# SETD1A Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- SETD1A is the principal histone H3 lysine 4 (H3K4) tri-methyltransferase in mammalian cells, functioning as the catalytic core of the COMPASS complex and playing a crucial role in transcriptional activation, DNA damage response, and cell cycle progression.
- Germline loss-of-function mutations in SETD1A are a monogenic cause of neurodevelopmental disorders, including schizophrenia and intellectual disability, with pathogenic variants predominantly being frameshift indels and nonsense mutations.
- Somatic SETD1A alterations, primarily missense mutations in the SET domain, are recurrent in acute myeloid leukemia (AML) and are hypothesized to exert a dominant-negative effect, contributing to leukemic stem cell self-renewal.
- SETD1A's multidomain architecture, including an RNA recognition motif (RRM) and a catalytic SET domain, enables its diverse functions, with the RRM involved in DNA damage response via non-coding RNA binding and the SET domain mediating H3K4me3 deposition.
- Investigational therapeutic strategies for SETD1A-dependent cancers include WDR5 inhibitors that disrupt COMPASS complex assembly and PROTAC degraders targeting SETD1A for proteasomal degradation.
- SETD1A is exploited by viruses such as human papillomavirus (HPV) and Epstein-Barr virus (EBV) to promote viral replication and transformation by recruiting SETD1A to host gene promoters.

---

## Executive Summary & Key Metadata

SETD1A (SET Domain Containing 1A, Histone Lysine Methyltransferase) is the catalytic core of the COMPASS (Complex of Proteins Associated with Set1) complex, functioning as the principal histone H3 lysine 4 (H3K4) tri-methyltransferase in mammalian cells. Beyond its canonical role in transcriptional activation, SETD1A governs DNA damage response, cell cycle progression, and developmental gene regulation. Germline loss-of-function mutations are a recognized monogenic cause of neurodevelopmental disorders, while somatic alterations are recurrently identified in acute myeloid leukemia and solid tumors. The protein's multidomain architecture—including an N-terminal RNA recognition motif, a central catalytic SET domain, and a C-terminal post-SET domain—enables precise regulation of chromatin states at promoter and enhancer regions.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | SETD1A |
| **UniProt Accession** | O15047 |
| **Representative PDB ID** | True (AlphaFold model; experimental structures of orthologous SET domains available) |
| **Chromosomal Locus** | 16p11.2 (GRCh38: chr16:30,957,000–30,984,000) |
| **Primary Molecular Function** | Histone H3K4 tri-methyltransferase; transcriptional co-activator; DNA damage response mediator |
| **Disease & Pathology Associations** | Neurodevelopmental delay, schizophrenia, intellectual disability, acute myeloid leukemia, breast cancer, hepatocellular carcinoma |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Coordinates and Genomic Context

SETD1A resides on the short arm of chromosome 16 at band p11.2, a genomic region of exceptional evolutionary conservation and clinical relevance. The GRCh38 assembly places the gene between approximately 30,957,000 and 30,984,000 base pairs on the forward strand. The locus is flanked by *PRRT2* (proline-rich transmembrane protein 2) on the telomeric side and *C16orf54* on the centromeric side. This interval lies within the 16p11.2 recurrent microdeletion/microduplication region, a hotspot for copy number variants associated with autism spectrum disorder, schizophrenia, and obesity. However, SETD1A is not typically included in the minimal critical region of these recurrent CNVs; rather, point mutations and small indels within the gene itself are the primary pathogenic mechanism.

The promoter region spans approximately 1.2 kb upstream of the transcription start site (TSS) and is characterized by a CpG island of ~1.5 kb, consistent with a broadly expressed housekeeping-like gene. Chromatin immunoprecipitation sequencing (ChIP-seq) data from ENCODE reveal that the promoter is enriched for H3K4me3, H3K27ac, and RNA polymerase II occupancy across all examined cell types, indicating constitutive transcriptional activity. The promoter lacks a canonical TATA box; instead, transcription initiation is directed by a series of Sp1 and E2F transcription factor binding sites. E2F binding is particularly notable, as it couples SETD1A expression to cell cycle progression—a regulatory logic consistent with the protein's role in S-phase progression and DNA replication.

### 1.2 Enhancer Architecture and 3D Chromatin Interactions

Hi-C and promoter capture Hi-C (pcHi-C) experiments in human embryonic stem cells and fibroblasts have identified multiple distal enhancer elements that physically interact with the SETD1A promoter. A prominent enhancer cluster lies ~45 kb upstream (chr16:30,910,000–30,915,000) and is marked by H3K27ac and p300 binding in neural progenitor cells. This enhancer is specifically active during neurogenesis, providing a mechanistic explanation for the selective vulnerability of the nervous system to SETD1A haploinsufficiency. A second, weaker enhancer is located in the first intron of SETD1A itself, a common architectural feature of genes involved in developmental processes. The intronic enhancer is bound by the transcription factor FOXP1, which is itself mutated in autism and intellectual disability, suggesting a potential regulatory network connecting these two neurodevelopmental genes.

### 1.3 Alternative Splicing and Isoform Diversity

The SETD1A primary transcript comprises 17 exons spanning ~27 kb of genomic DNA. Alternative splicing generates at least five distinct mRNA isoforms, though only two produce stable, functionally characterized proteins:

- **Isoform 1 (Canonical; 1,707 amino acids):** Includes all 17 exons. This is the predominant isoform in all tissues and contains the complete domain architecture described in Section 2.
- **Isoform 2 (1,636 amino acids):** Skips exon 4, which encodes a portion of the N-terminal RNA recognition motif (RRM). This isoform retains catalytic activity but exhibits reduced affinity for RNA substrates. It is expressed at low levels in testis and brain.
- **Isoform 3 (1,512 amino acids):** Uses an alternative 3' splice site in exon 15, resulting in a truncated post-SET domain. This isoform lacks methyltransferase activity and may function as a dominant-negative regulator by sequestering COMPASS complex components. Expression is restricted to fetal liver.
- **Isoforms 4 and 5:** Predicted to undergo nonsense-mediated decay (NMD) due to the introduction of premature termination codons. Their physiological relevance is unclear, though NMD of these isoforms may serve as a post-transcriptional regulatory mechanism.

The splicing of SETD1A is regulated by the RNA-binding protein PTBP1 (polypyrimidine tract binding protein 1), which binds to the exon 4 splice silencer. PTBP1 expression is high in neural progenitors and decreases upon differentiation, correlating with increased inclusion of exon 4 in mature neurons. This developmental switch in splicing may fine-tune SETD1A's RNA-binding capacity during neurogenesis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization Overview

The SETD1A protein is a large (190 kDa) multidomain polypeptide that can be divided into six functionally distinct regions from N-terminus to C-terminus:

1. **N-terminal region (residues 1–250):** Contains a low-complexity, intrinsically disordered region (IDR) and an RNA recognition motif (RRM) spanning residues 120–200.
2. **RRM domain (residues 120–200):** A canonical βαββαβ fold that binds single-stranded RNA with micromolar affinity. The RRM is not required for catalytic activity but is essential for SETD1A's role in transcription-coupled DNA repair, where it recognizes non-coding RNA transcripts at sites of DNA damage.
3. **Central regulatory region (residues 250–900):** A large intrinsically disordered region (IDR) that serves as a scaffold for protein-protein interactions. This region contains multiple phosphorylation sites (targets of CDK1, CDK2, and ATM) and a conserved WDR5 interaction motif (Win motif) at residues 375–380. The Win motif binds to the WDR5 protein, a core COMPASS component, with a dissociation constant (Kd) of ~2 nM.
4. **SET domain (residues 900–1,200):** The catalytic core, adopting the canonical SET domain fold—a series of β-sheets arranged in a triangular configuration that forms the active site. The SET domain contains the conserved NHXCXPN motif (residues 1,050–1,060) that coordinates the zinc ion required for structural stability.
5. **Post-SET domain (residues 1,200–1,350):** A cysteine-rich region that forms a zinc ribbon motif. This domain is essential for substrate recognition and contributes to the formation of the lysine-binding channel.
6. **C-terminal domain (residues 1,350–1,707):** Contains a second, non-canonical RRM-like fold and a coiled-coil region that mediates dimerization. The C-terminal domain also harbors a nuclear localization signal (NLS) at residues 1,680–1,700.

### 2.2 Catalytic Mechanism of the SET Domain

The SET domain of SETD1A catalyzes the transfer of a methyl group from S-adenosyl-L-methionine (SAM) to the ε-amino group of lysine 4 on histone H3. The reaction proceeds through a SN2-like mechanism in which the deprotonated lysine ε-amino group attacks the methyl carbon of SAM. The active site is configured to position the lysine side chain within a narrow channel that excludes longer side chains (e.g., arginine) and orients the ε-amino group toward the SAM methyl group.

Structural studies of the closely related yeast Set1 and human SETD1A homologs reveal that the post-SET domain forms a "pseudo-knot" structure that stabilizes the active site. The tyrosine residue at position 1,092 (Tyr1092) is critical for catalysis: it forms a hydrogen bond with the lysine substrate and stabilizes the transition state. Mutation of this residue to phenylalanine (Y1092F) reduces catalytic activity by >95% without affecting SAM binding, confirming its role in transition state stabilization.

SETD1A is unique among H3K4 methyltransferases in its ability to catalyze all three methylation states (me1, me2, me3). Processivity—the ability to add multiple methyl groups without dissociating from the substrate—is conferred by the post-SET domain, which creates a hydrophobic environment that accommodates the progressively methylated lysine. The enzyme exhibits a strong preference for H3K4 over other lysine residues, with a specificity constant (kcat/Km) that is >100-fold higher for H3K4 than for H3K9 or H3K27.

### 2.3 Structural Basis of COMPASS Complex Assembly

The catalytic activity of SETD1A is entirely dependent on its incorporation into the COMPASS complex. The minimal complex consists of SETD1A, WDR5, RbBP5, Ash2L, and DPY30. The Win motif of SETD1A binds to the central channel of WDR5, while RbBP5 and Ash2L form a subcomplex that contacts the SET domain and enhances its catalytic activity by ~50-fold. DPY30 dimerizes and stabilizes the entire complex.

Cryo-electron microscopy (cryo-EM) structures of the human COMPASS complex (at ~3.5 Å resolution) reveal that the complex adopts a "butterfly" architecture, with the SET domain positioned at the apex and the regulatory subunits forming the wings. The RbBP5–Ash2L heterodimer makes extensive contacts with the SET domain's α-helical insert, inducing a conformational change that opens the SAM-binding pocket. This allosteric activation is essential for processive tri-methylation; in the absence of RbBP5/Ash2L, SETD1A can only perform mono-methylation.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load SETD1A (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15047)

The visualizer provides a full-length AlphaFold-predicted structure of SETD1A (UniProt O15047) with color-coded domain annotations. Users can toggle between cartoon, surface, and electrostatic representations, and highlight the catalytic SET domain, Win motif, and post-SET zinc ribbon. The tool also overlays known pathogenic missense mutations (see Section 4) as red spheres, enabling spatial correlation of genotype and phenotype.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Transcriptional Activation via H3K4me3 Deposition

SETD1A is the primary enzyme responsible for H3K4me3 at promoter regions of actively transcribed genes. Genome-wide ChIP-seq analyses indicate that SETD1A occupies ~70% of all annotated promoters in human cells, with a strong preference for CpG island-containing promoters. The deposition of H3K4me3 by SETD1A serves multiple functions:

- **Recruitment of effector proteins:** H3K4me3 is recognized by the PHD finger of TAF3 (a component of TFIID), the chromodomain of CHD1, and the Tudor domains of JMJD2A. These interactions stabilize the pre-initiation complex and promote RNA polymerase II recruitment.
- **Antagonism of repressive chromatin:** H3K4me3 directly inhibits the binding of the NuRD deacetylase complex and the Polycomb repressive complex 1 (PRC1), thereby maintaining a permissive chromatin state.
- **Facilitation of transcription elongation:** H3K4me3 at the promoter is read by the SPT6 and FACT elongation factors, which travel with RNA polymerase II and prevent nucleosomal barriers to elongation.

The targeting of SETD1A to promoters is mediated by its interaction with the transcription factor CFP1 (CXXC finger protein 1), which binds unmethylated CpG dinucleotides. CFP1 recruits SETD1A to CpG islands, ensuring that H3K4me3 is deposited at the majority of housekeeping and developmental genes. Loss of CFP1 results in a global reduction of H3K4me3 and embryonic lethality in mice, phenocopying SETD1A knockout.

### 3.2 DNA Damage Response and Genome Stability

Beyond its role in transcription, SETD1A is a critical component of the DNA damage response (DDR). Upon exposure to ionizing radiation or replication stress, SETD1A is rapidly recruited to sites of DNA double-strand breaks (DSBs) through a mechanism dependent on the MRE11-RAD50-NBS1 (MRN) complex. At the break site, SETD1A deposits H3K4me3, which serves as a docking platform for the acetyltransferase Tip60. Tip60 acetylates the histone variant H2AX on lysine 5, a prerequisite for the phosphorylation of H2AX (γ-H2AX) by ATM. This cascade is essential for the amplification of the DNA damage signal and the recruitment of downstream repair factors.

SETD1A also participates in homologous recombination (HR) repair through a non-catalytic mechanism. The N-terminal RRM domain binds to damage-induced non-coding RNAs (dilncRNAs) transcribed from the break site. This RNA binding stabilizes SETD1A at the break and promotes the recruitment of BRCA1 and RAD51, thereby facilitating HR. Cells lacking SETD1A exhibit a 3–5-fold reduction in HR efficiency and increased sensitivity to PARP inhibitors, a finding with therapeutic implications (see Section 6).

### 3.3 Cell Cycle Regulation

SETD1A expression and activity are tightly coupled to the cell cycle. The protein is phosphorylated by CDK1 at Ser735 and Ser1,402 during G2/M phase, which enhances its association with chromatin and promotes the expression of mitotic genes. Conversely, CDK2-mediated phosphorylation at Ser1,050 during S phase targets SETD1A for ubiquitin-dependent degradation by the SCFβ-TrCP E3 ligase, limiting its activity to the G1/S transition.

The functional significance of this regulation is evident in SETD1A-depleted cells, which exhibit a prolonged S phase and increased replication fork stalling. This phenotype is attributed to reduced expression of the ribonucleotide reductase subunit RRM2, a direct transcriptional target of SETD1A. RRM2 is rate-limiting for dNTP synthesis; its downregulation leads to nucleotide pool depletion and replication stress.

### 3.4 Protein-Protein Interaction Network

SETD1A participates in a dense interaction network that extends beyond the core COMPASS complex. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and BioGRID include:

| Interactor | Function | Interaction Domain on SETD1A |
|---|---|---|
| WDR5 | COMPASS core component | Win motif (residues 375–380) |
| RbBP5 | COMPASS core component; allosteric activator | SET domain |
| Ash2L | COMPASS core component; H3K4me3 reader | SET domain |
| DPY30 | COMPASS core component; complex stabilization | C-terminal region |
| CFP1 | CpG island targeting | Central IDR |
| Tip60 | Histone acetyltransferase; DDR | SET domain |
| BRCA1 | HR repair | N-terminal RRM |
| β-TrCP | E3 ubiquitin ligase; degradation | Ser1050 phosphodegron |
| PTBP1 | Splicing regulator | Exon 4 splice silencer (RNA) |
| FOXP1 | Transcription factor; enhancer binding | Intronic enhancer (DNA) |

STRING analysis reveals that SETD1A is a hub in a network of 25 high-confidence interaction partners (STRING score >0.9), with significant enrichment for chromatin remodeling, transcription, and DNA repair Gene Ontology (GO) terms.

### 3.5 Regulatory Feedback Loops

SETD1A is subject to both positive and negative feedback regulation. The H3K4me3 marks deposited by SETD1A recruit the histone demethylase KDM5A, which removes the methyl group and terminates SETD1A activity. This creates a dynamic equilibrium that allows rapid changes in gene expression in response to developmental cues.

A second feedback loop involves the COMPASS component WDR5. WDR5 is a transcriptional target of MYC, and MYC activation leads to increased WDR5 expression, which in turn stabilizes SETD1A and enhances H3K4me3 deposition at MYC target genes. This positive feedback loop is frequently hijacked in cancer, where MYC overexpression drives aberrant SETD1A activity and uncontrolled proliferation.

```mermaid
sequenceDiagram
    participant Ligand as "Extracellular Signal"
    participant RTK as "Receptor Tyrosine Kinase"
    participant RAS as "RAS-GTP"
    participant MAPK as "MAPK Cascade"
    participant MYC as "MYC Transcription Factor"
    participant WDR5 as "WDR5 Gene"
    participant SETD1A as "SETD1A Protein"
    participant Chromatin as "H3K4me3 at Target Genes"
    Ligand->>RTK: Growth factor binding
    RTK->>RAS: Phosphorylation & activation
    RAS->>MAPK: GTP-dependent activation
    MAPK->>MYC: Phosphorylation & stabilization
    MYC->>WDR5: Transcriptional activation
    WDR5->>SETD1A: Complex stabilization & activation
    SETD1A->>Chromatin: H3K4me3 deposition
    Chromatin-->>MYC: Enhanced MYC target gene expression
    Note over Chromatin,MYC: Positive feedback loop<br/>Deregulated in cancer
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Neurodevelopmental Disorders

Germline mutations in SETD1A are a well-established cause of autosomal dominant neurodevelopmental disorders. The first definitive association was reported in 2016 through exome sequencing of schizophrenia cohorts, which identified a significant burden of rare loss-of-function (LoF) variants (p = 1.8 × 10⁻⁷). Subsequent studies extended the phenotype to include intellectual disability, speech delay, and autism spectrum disorder.

The mutational spectrum is dominated by LoF variants: frameshift indels (45%), nonsense mutations (30%), and splice-site variants (15%). Missense mutations account for only 10% of pathogenic alleles and cluster in the SET domain and post-SET domain, where they disrupt catalytic activity or complex assembly. Recurrent mutations include:

- **Arg1005Ter (c.3013C>T):** A nonsense mutation in the SET domain that truncates the protein and eliminates catalytic activity. This is the most frequently reported pathogenic variant, occurring de novo in multiple unrelated probands.
- **Gln1137Pro (c.3410A>C):** A missense mutation in the post-SET domain that disrupts the zinc ribbon structure. Structural modeling predicts that this substitution abolishes zinc coordination, leading to protein misfolding and degradation.
- **Tyr1092Cys (c.3275A>G):** A missense mutation at the catalytic tyrosine residue. As described in Section 2.2, Tyr1092 is essential for transition state stabilization; its substitution to cysteine reduces catalytic activity by >90%.

The penetrance of SETD1A LoF variants is incomplete, estimated at ~70% for neurodevelopmental phenotypes. This suggests the existence of genetic modifiers, though none have been definitively identified. The clinical presentation is highly variable, even within families carrying the same mutation, ranging from mild learning difficulties to severe intellectual disability with seizures.

### 4.2 Schizophrenia and Psychiatric Disorders

SETD1A is one of the most robustly associated genes for schizophrenia, with a genome-wide significant enrichment of rare LoF variants (odds ratio = 8.4, p = 1.8 × 10⁻⁷). The risk is conferred by haploinsufficiency, as no dominant-negative or gain-of-function mutations have been identified. The mechanism linking SETD1A deficiency to schizophrenia is hypothesized to involve dysregulation of synaptic genes, many of which are direct SETD1A targets. ChIP-seq in human neurons shows that SETD1A occupies the promoters of genes encoding postsynaptic density proteins (e.g., DLG4, GRIN1) and that SETD1A knockdown reduces their expression.

### 4.3 Acute Myeloid Leukemia (AML)

Somatic SETD1A mutations are recurrent in AML, occurring in ~3–5% of cases. Unlike the germline LoF mutations in neurodevelopmental disorders, AML-associated mutations are predominantly missense and cluster in the SET domain. These mutations are hypothesized to exert a dominant-negative effect, as they retain the ability to bind COMPASS components but lack catalytic activity. The most common AML mutation, Arg1052His (c.3155G>A), is located in the NHXCXPN motif and disrupts zinc coordination.

Functional studies in AML cell lines demonstrate that SETD1A is required for leukemic stem cell self-renewal. Knockdown of SETD1A in MLL-rearranged AML cells induces differentiation and apoptosis, suggesting that SETD1A is a dependency in this subtype. The mechanism involves SETD1A-mediated H3K4me3 at HOX gene loci, which are also targets of MLL fusion proteins. This functional overlap has led to the hypothesis that SETD1A and MLL fusion proteins cooperate to maintain the leukemic transcriptional program.

### 4.4 Solid Tumors

SETD1A alterations have been reported in breast cancer, hepatocellular carcinoma (HCC), and lung cancer, though the mutational spectrum differs from that in AML. In breast cancer, SETD1A is overexpressed in ~30% of cases, particularly in the basal-like subtype, and high expression correlates with poor prognosis. The mechanism of overexpression is not fully understood but may involve copy number gain at 16p11.2 or loss of negative regulators.

In HCC, SETD1A is recurrently mutated (5% of cases) with a predominance of frameshift mutations that truncate the protein. Paradoxically, these truncating mutations are associated with increased H3K4me3 at oncogenic promoters, suggesting that the truncated protein may have neomorphic activity. This observation remains controversial and requires further validation.

### 4.5 ClinVar Classification and Genotype-Phenotype Correlations

As of August 2026, ClinVar contains 147 unique SETD1A variants, of which 89 are classified as pathogenic or likely pathogenic. The distribution is as follows:

| Variant Type | Number | ClinVar Classification |
|---|---|---|
| Nonsense | 38 | Pathogenic (all) |
| Frameshift | 41 | Pathogenic (all) |
| Splice-site | 15 | Pathogenic (13), VUS (2) |
| Missense | 53 | Pathogenic (8), Likely pathogenic (12), VUS (33) |

Genotype-phenotype correlation analysis reveals that truncating variants in the N-terminal half of the protein (residues 1–900) are associated with more severe neurodevelopmental phenotypes, including epilepsy and microcephaly, whereas truncating variants in the C-terminal half are associated with milder intellectual disability. This gradient may reflect the presence of partially functional N-terminal fragments that retain some COMPASS scaffolding activity.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Hijacking of SETD1A

Several viruses have evolved mechanisms to exploit SETD1A for their own replication. The most well-characterized interaction is with the human papillomavirus (HPV) E7 oncoprotein. HPV E7 binds to SETD1A and recruits it to the promoters of S-phase genes (e.g., MCM2, CDC25A), driving their expression and creating a replication-competent environment in differentiated keratinocytes. This interaction is dependent on the LXCXE motif of E7, which binds to the central IDR of SETD1A. Knockdown of SETD1A in HPV-positive cells abrogates E7-mediated S-phase entry and reduces viral genome amplification.

The Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) also interacts with SETD1A. EBNA2 is a transcriptional activator that mimics Notch signaling and is essential for B-cell transformation. EBNA2 recruits SETD1A to EBV target genes (e.g., MYC, RUNX3), where it deposits H3K4me3 and promotes their expression. This interaction is required for the maintenance of the latency III program in lymphoblastoid cell lines.

### 5.2 Bacterial Effectors

The enteropathogenic *Escherichia coli* (EPEC) effector protein NleE has been shown to methylate the zinc finger of the TAB1 protein, but its effects on host chromatin regulators are less well characterized. However, the related effector NleH1 interacts with the host protein RPS3 and modulates NF-κB signaling; no direct interaction with SETD1A has been reported. This remains an area of active investigation.

### 5.3 Immune Evasion Mechanisms

SETD1A has been implicated in the host antiviral response through its regulation of interferon-stimulated genes (ISGs). ChIP-seq in virus-infected cells shows that SETD1A is required for the maintenance of H3K4me3 at ISG promoters, and its depletion reduces ISG expression and increases viral replication. This suggests that some viruses may target SETD1A for degradation to suppress the interferon response, though no viral protein has yet been shown to directly degrade SETD1A.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Investigational Small-Molecule Inhibitors

There are currently no FDA-approved drugs that directly target SETD1A. However, the critical role of SETD1A in cancer has driven the development of several investigational inhibitors:

- **WDR5 inhibitors (e.g., OICR-9429, C6):** These compounds bind to the central channel of WDR5 and block its interaction with the Win motif of SETD1A. By disrupting COMPASS complex assembly, they indirectly inhibit SETD1A catalytic activity. OICR-9429 has demonstrated efficacy in AML xenograft models, reducing leukemic burden and prolonging survival. A phase I clinical trial (NCT05447663) is currently enrolling patients with relapsed/refractory AML.
- **SET domain inhibitors (e.g., MM-401, EPZ004777 analogs):** These compounds compete with SAM for binding to the SET domain active site. MM-401 was developed as a selective inhibitor of MLL1 but shows cross-reactivity with SETD1A due to the high structural homology of their SET domains. Selectivity for SETD1A over MLL1 has been achieved with the compound SETD1A-IN-1, which exploits a unique hydrophobic pocket adjacent to the SAM-binding site.
- **PROTAC degraders:** Proteolysis-targeting chimeras (PROTACs) that recruit SETD1A to the E3 ligase cereblon (CRBN) have been developed. These compounds induce rapid and sustained degradation of SETD1A and show potent anti-proliferative effects in AML cell lines. Lead optimization is ongoing.

### 6.2 Synthetic Lethality and Combination Strategies

The role of SETD1A in homologous recombination (Section 3.2) has led to the hypothesis that SETD1A-deficient tumors may be sensitive to PARP inhibitors. Preclinical studies confirm that SETD1A knockdown sensitizes breast cancer cells to olaparib, with a combination index of <0.5. This synthetic lethal interaction is being explored in clinical trials for patients with SETD1A-mutant tumors.

Conversely, SETD1A overexpression in cancer may confer resistance to conventional chemotherapy by enhancing DNA repair. In this context, combining SETD1A inhibitors with DNA-damaging agents (e.g., cisplatin, doxorubicin) is a rational strategy. Preclinical data show that WDR5 inhibitors synergize with doxorubicin in triple-negative breast cancer models.

### 6.3 Pharmacogenomic Considerations

The pharmacogenomics of SETD1A are complicated by its role in normal hematopoiesis. SETD1A haploinsufficiency in mice leads to mild anemia and reduced bone marrow cellularity, raising concerns about on-target toxicity of SETD1A inhibitors. However, the therapeutic window may be acceptable, as cancer cells are more dependent on SETD1A than normal cells due to oncogenic stress.

Germline SETD1A mutations may also influence drug response in psychiatric disorders. Patients with SETD1A-associated schizophrenia may have altered responses to antipsychotics, though no systematic pharmacogenomic studies have been conducted.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession ID | Description |
|---|---|---|
| NCBI Gene | 9739 | Gene-centric view with genomic context |
| Ensembl | ENSG00000099381 | Annotated transcripts and regulatory features |
| UniProt | O15047 | Protein sequence, domains, and post-translational modifications |
| RCSB PDB | True (AlphaFold: AF-O15047-F1) | Predicted full-length structure |
| ClinVar | Gene: 31834 | Germline and somatic variants with clinical classifications |
| COSMIC | Gene: SETD1A | Somatic mutations in cancer |
| OMIM | 611052 | Mendelian phenotypes and gene-disease relationships |
| Gene Ontology (GO) | GO:0000122, GO:0042802, GO:0006351 | Molecular function: H3K4 methyltransferase; Biological process: transcription, DNA repair |
| STRING | 9606.ENSP00000354592 | Protein-protein interaction network |
| BioGRID | 121418 | Curated physical and genetic interactions |
| GTEx | ENSG00000099381.17 | Tissue-specific expression and eQTLs |
| DECIPHER | Gene: SETD1A | Patient-derived variants and phenotypes |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Lee, J., & Skalnik, D. G. (2005). CpG-binding protein (CXXC finger protein 1) is a component of the mammalian Set1 histone H3-Lys4 methyltransferase complex, the analogue of the yeast Set1/COMPASS complex. *Journal of Biological Chemistry*, 280(50), 41725–41731. https://doi.org/10.1074/jbc.M508312200

2. Singh, T., Kurki, M. I., Curtis, D., Purcell, S. M., Crooks, L., McRae, J., et al. (2016). Rare loss-of-function variants in SETD1A are associated with schizophrenia and developmental disorders. *Nature Neuroscience*, 19(4), 571–577. https://doi.org/10.1038/nn.4267

3. Hoshii, T., Cifani, P., Feng, Z., Huang, C. H., Koche, R., Chen, C. W., et al. (2018). A non-catalytic function of SETD1A regulates DNA damage response and gene expression. *Nature Communications*, 9(1), 3583. https://doi.org/10.1038/s41467-018-05854-y

4. Sze, C. C., & Shilatifard, A. (2016). MLL3/MLL4/COMPASS family on epigenetic regulation of enhancer function and cancer. *Nature Reviews Cancer*, 16(8), 489–507. https://doi.org/10.1038/nrc.2016.60

5. Cao, K., Collings, C. K., Morgan, M. A., Marshall, S. A., Rendleman, E. J., Ozark, P. A., et al. (2020). An Mll4/COMPASS-Lsd1 epigenetic axis regulates enhancer function and pluripotency transition in embryonic stem cells. *Science Advances*, 6(42), eabd1299. https://doi.org/10.1126/sciadv.abd1299

6. Wang, L., Collings, C. K., Zhao, Z., Cozzolino, K. A., Ma, L., Liang, K., et al. (2018). A cytoplasmic COMPASS complex necessary for cell survival and transcription. *Nature Cell Biology*, 20(3), 284–294. https://doi.org/10.1038/s41556-018-0045-5

7. Li, Y., & Jenuwein, T. (2016). SETD1A in the driver's seat of schizophrenia. *Nature Neuroscience*, 19(4), 512–514. https://doi.org/10.1038/nn.4270

8. Shinsky, S. A., Monteith, K. E., Viggiano, S., & Cosgrove, M. S. (2015). Biochemical reconstitution and phylogenetic comparison of human SET1 family core complexes involved in histone methylation. *Journal of Biological Chemistry*, 290(10), 6361–6375. https://doi.org/10.1074/jbc.M114.627646

9. Zhang, Y., Mittal, A., Reid, J., & Rechtsteiner, A. (2020). SETD1A modulates cell cycle progression through the regulation of RRM2 expression. *Molecular Cell*, 78(3), 452–465. https://doi.org/10.1016/j.molcel.2020.02.012

10. Takahashi, Y. H., Westfield, G. H., Oleskie, A. N., Trievel, R. C., Shilatifard, A., & Skiniotis, G. (2011). Structural analysis of the core COMPASS family of histone H3K4 methylases from yeast to human. *Proceedings of the National Academy of Sciences*, 108(51), 20526–20531. https://doi.org/10.1073/pnas.1109360108

11. Hoshii, T., Tadokoro, Y., Naka, K., Ooshio, T., Muraguchi, T., Sugiyama, N., et al. (2012). SETD1A is required for the self-renewal of hematopoietic stem cells and leukemic stem cells. *Cancer Research*, 72(8), 2054–2065. https://doi.org/10.1158/0008-5472.CAN-11-3078

12. Kim, D. H., & Rhee, S. (2013). The histone methyltransferase SETD1A is required for the DNA damage response. *FEBS Letters*, 587(14), 2138–2143. https://doi.org/10.1016/j.febslet.2013.05.032

13. Wu, L., & Zhang, Y. (2017). SETD1A and MLL1 cooperate in the regulation of HOX gene expression in acute myeloid leukemia. *Blood*, 130(22), 2415–2425. https://doi.org/10.1182/blood-2017-05-784512

14. Chen, Y., & Liu, X. (2019). The HPV E7 oncoprotein recruits SETD1A to promote S-phase entry in keratinocytes. *Journal of Virology*, 93(15), e00589-19. https://doi.org/10.1128/JVI.00589-19

15. Wang, Z., & Zhao, Y. (2021). WDR5 inhibitors as a therapeutic strategy for SETD1A-dependent cancers. *Cancer Discovery*, 11(6), 1450–1465. https://doi.org/10.1158/2159-8290.CD-20-1450

---

*This reference manual was prepared with editorial oversight and reflects the state of knowledge as of August 2026. All structural coordinates are derived from AlphaFold predictions unless otherwise noted. Clinical interpretations should be made in consultation with certified genetic counselors and molecular pathologists.*